

March 21, 2025

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
---	---

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is to inform you that Curateq Biologics Private Limited, a wholly owned subsidiary of the Company ("Curateq") has allotted 4,125,055 Compulsory Convertible Preference Shares (CCPSs) of Rs.10/- each to Dr. Satakarni Makkapati on March 20, 2025. Each CCPS is convertible into a maximum of one equity share of Rs.10/- each and on conversion into Equity Shares Dr. Satakarni Makkapati will be holding 2% of Equity Share capital of Curateq and Curateq will then cease to be a wholly owned subsidiary of the Company and continue as a subsidiary of the Company.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as **Annexure**.

This is for your information and records.

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary

Enclosure: Annexure

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad-500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Annexure
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

a	the amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year;	<p>The turnover of Curateq Biologics Private Limited, a wholly owned subsidiary of the Company (“Curateq”) is as under:</p> <p>Turnover for the financial year ended 31.03.2024: Rs.0.01 million and it is yet to start commercial operations.</p> <p>Net-worth:</p> <p>As on 31.03.2024 : Rs. (9,963.63) million</p> <p>As on 31.12.2024 (Unaudited): Rs. (14,959.93) million</p> <p>Debt:</p> <p>As on 31.03.2024 : Rs. 20,707.06 million</p> <p>As on 31.12.2024 (Unaudited) : Rs. 27,406.28 million</p>						
b	date on which the agreement for sale has been entered into;	<p>A Share Subscription and Shareholders Agreement (“SSSA”) has been entered into on March 20, 2025.</p> <p>As per SSSA, Curateq on March 20, 2025 has allotted 4,125,055 Compulsory Convertible Preference Shares (“CCPSs”) of Rs.10 each at a price of Rs. 11.02 and each CCPS is convertible into a maximum of one equity share of Rs.10/- each within a maximum period of 20 years from the date of allotment to Dr. Satakarni Makkapati.</p> <p>On conversion of CCPSs into equity shares, Dr. Satakarni Makkapati will be holding a maximum of 2% of the equity share capital of Curateq and Curateq will then cease to be a wholly owned subsidiary and continue as a subsidiary of the Company.</p> <p>Post conversion of CCPSs into equity shares, following would be the shareholding pattern of Curateq:</p> <table><tr><td>Name of the Shareholder</td><td>% of holding</td></tr><tr><td>Aurobindo Pharma Limited (Holding company)</td><td>98%</td></tr><tr><td>Dr. Satakarni Makkapati</td><td>2%</td></tr></table>	Name of the Shareholder	% of holding	Aurobindo Pharma Limited (Holding company)	98%	Dr. Satakarni Makkapati	2%
Name of the Shareholder	% of holding							
Aurobindo Pharma Limited (Holding company)	98%							
Dr. Satakarni Makkapati	2%							
c	the expected date of completion of sale/disposal;	Not applicable						
d	consideration received from such sale/disposal;	Rs. 22.73 million as share application money and the balance Rs. 22.73 million at the time of further calls undertaken by Curateq.						

AUROBINDO PHARMA LIMITED
www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad-500038 Telangana., India Tel: +91 40 2373 6370 / 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

e	brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;	Dr. Satakarni Makkapati does not belong to the promoter/ promoter group / group companies.
f	whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”;	Dr. Satakarni Makkapati is Chief Executive Officer of Curateq and a Director of Aurobindo Pharma Limited. As per the SEBI (LODR) Regulations, 2015, the issue of specified securities on a preferential basis is not a related party transaction.
g	whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.	Not applicable
h	additionally, in case of a slump sale, indicative disclosures provided for amalgamation/ merger, shall be disclosed by the listed entity with respect to such slump sale.	Not applicable

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad-500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com